Avenge Bio, Inc.
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Holding
- Established
- 2019-01-01
- Employees
- 11
- Market Cap
- -
- Website
- http://avengebio.com
A Study of Intraperitoneally Administered AVB-001 in Patients With Serous Adenocarcinoma of the Ovary
Phase 1
Terminated
- Conditions
- Serous Adenocarcinoma of OvarySerous Adenocarcinoma of Primary PeritoneumNeoplasm, OvarianPrimary Peritoneal Cavity CancerPrimary Peritoneal CarcinomaHigh Grade Serous AdenocarcinomaFallopian Tube CancerAdenocarcinoma Ovary
- Interventions
- First Posted Date
- 2022-09-14
- Last Posted Date
- 2024-04-24
- Lead Sponsor
- Avenge Bio, Inc
- Target Recruit Count
- 14
- Registration Number
- NCT05538624
- Locations
- 🇺🇸
Massachusetts General Hospital, Boston, Massachusetts, United States
🇺🇸National Cancer Institute, Bethesda, Maryland, United States
🇺🇸UPMC Magee-Womens Hospital, Pittsburgh, Pennsylvania, United States
© Copyright 2025. All Rights Reserved by MedPath